CD274 and rectal cancer: Further analysis of PD-L1 in rectal cancer is warranted, ideally in larger series including patients treated with TNT, which has recently become a new standard of care for locally advanced tumours, and/or with immune checkpoint inhibitors to allow exploring both the prognostic and predictive value of this biomarker.